GlassScriptPhysician profile
Jessica Hernandez
NPI 1962166504
$3,763.67
in general payments reported to CMS, 2019-2025
18 companies · $3,458 in 2025
The $3,458 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.97 · 2024: $268 · 2025: $3,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,726.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,725.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $762.62 | 2024-2025 | |
| Pfizer INC. | $462.20 | 2024-2025 | |
| Janssen Biotech, INC. | $449.35 | 2024-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $389.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $286.75 | 2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $225.11 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $220.85 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $200.60 | 2024-2025 | Entyvio, Eohilia |
| Celltrion USA INC. | $198.92 | 2024-2025 | Vegzelma, Zymfentra |
| Ardelyx, INC. | $132.01 | 2025 | Ibsrela |
| Enterra Medical, INC. | $116.07 | 2024-2025 | |
| Lilly USA, LLC | $97.14 | 2025 | Omvoh |
| Genzyme Corporation | $81.79 | 2025 | |
| Braintree Laboratories, INC. | $41.54 | 2025 | Suflave |
| Janssen Pharmaceuticals, INC | $37.97 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $24.40 | 2025 | Zenpep |
| Medtronic, INC. | $19.57 | 2025 | Inceptiv |
| Organon LLC | $17.48 | 2025 | Renflexis, Hadlima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.